Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT02224781
Title field or adapter rule
{'original_value': 'DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial', 'source_field': 'protocolSection.identificationModule.officialTitle'}
Ingested At
2026-10-31T23:27:29.823703+00:00
Published At
2026-02-18T00:00:00+00:00
Record Updated At
2026-10-26
Results Posted At
2026-02-18
Source Retrieved At
2026-10-31T22:18:13.198083+00:00
Timestamp Basis
ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter
Date limitation
ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Clinical Stage III Cutaneous Melanoma AJCC v8", "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Metastatic Melanoma", "Recurrent Melanoma", "Unresectable Melanoma"]
protocolSection.statusModule.lastUpdatePostDateStruct
{"date": "2026-10-26", "type": "ACTUAL"}
protocolSection.identificationModule.nctId
"NCT02224781"
protocolSection.identificationModule.officialTitle
"DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial"
protocolSection.statusModule.overallStatus
"ACTIVE_NOT_RECRUITING"
protocolSection.designModule.phases
["PHASE3"]
protocolSection.statusModule.resultsFirstPostDateStruct
{"date": "2026-02-18", "type": "ACTUAL"}

Study condition terms

  • Clinical Stage III Cutaneous Melanoma AJCC v8 (protocolSection.conditionsModule.conditions)
  • Clinical Stage IV Cutaneous Melanoma AJCC v8 (protocolSection.conditionsModule.conditions)
  • Metastatic Melanoma (protocolSection.conditionsModule.conditions)
  • Recurrent Melanoma (protocolSection.conditionsModule.conditions)
  • Unresectable Melanoma (protocolSection.conditionsModule.conditions)

Interventions recorded in this study

  • {'armGroupLabels': ['Arm A (immunotherapy)', 'Arm B (BRAF inhibitor therapy)', 'Arm C (BRAF inhibitor therapy)', 'Arm D (immunotherapy)'], 'description': 'Undergo collection of blood samples', 'name': 'Biospecimen Collection', 'type': 'PROCEDURE'} (protocolSection.armsInterventionsModule.interventions[])
  • {'armGroupLabels': ['Arm A (immunotherapy)', 'Arm B (BRAF inhibitor therapy)', 'Arm C (BRAF inhibitor therapy)', 'Arm D (immunotherapy)'], 'description': 'Undergo CT', 'name': 'Computed Tomography', 'type': 'PROCEDURE'} (protocolSection.armsInterventionsModule.interventions[])
  • {'armGroupLabels': ['Arm B (BRAF inhibitor therapy)', 'Arm C (BRAF inhibitor therapy)'], 'description': 'Given PO', 'name': 'Dabrafenib Mesylate', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
  • {'armGroupLabels': ['Arm A (immunotherapy)', 'Arm B (BRAF inhibitor therapy)', 'Arm C (BRAF inhibitor therapy)', 'Arm D (immunotherapy)'], 'description': 'Undergo ECHO', 'name': 'Echocardiography Test', 'type': 'PROCEDURE'} (protocolSection.armsInterventionsModule.interventions[])
  • {'armGroupLabels': ['Arm A (immunotherapy)', 'Arm D (immunotherapy)'], 'description': 'Given IV', 'name': 'Ipilimumab', 'type': 'BIOLOGICAL'} (protocolSection.armsInterventionsModule.interventions[])
  • {'armGroupLabels': ['Arm A (immunotherapy)', 'Arm B (BRAF inhibitor therapy)', 'Arm C (BRAF inhibitor therapy)', 'Arm D (immunotherapy)'], 'description': 'Undergo MUGA scan', 'name': 'Multigated Acquisition Scan', 'type': 'PROCEDURE'} (protocolSection.armsInterventionsModule.interventions[])
  • {'armGroupLabels': ['Arm A (immunotherapy)', 'Arm D (immunotherapy)'], 'description': 'Given IV', 'name': 'Nivolumab', 'type': 'BIOLOGICAL'} (protocolSection.armsInterventionsModule.interventions[])
  • {'armGroupLabels': ['Arm A (immunotherapy)', 'Arm B (BRAF inhibitor therapy)', 'Arm C (BRAF inhibitor therapy)', 'Arm D (immunotherapy)'], 'description': 'Ancillary studies', 'name': 'Quality-of-Life Assessment', 'type': 'OTHER'} (protocolSection.armsInterventionsModule.interventions[])
  • {'armGroupLabels': ['Arm B (BRAF inhibitor therapy)', 'Arm C (BRAF inhibitor therapy)'], 'description': 'Given PO', 'name': 'Trametinib Dimethyl Sulfoxide', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

Drug names recorded in this source

  • Dabrafenib Mesylate (protocolSection.armsInterventionsModule.interventions[].name)
  • Trametinib Dimethyl Sulfoxide (protocolSection.armsInterventionsModule.interventions[].name)

A recorded drug name is not by itself an indication or a condition-specific relationship.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.